Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Outcomes of AML Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation with Adverse Risk Disease By European Leukemianet Classification: A Single Center Retrospective Analysis

Zane Chiad, MD, Clark Alsfeld, MD, Robert Collins, MD MPH, Brion Randolph, MD, Georges Nahhas, Robert K. Stuart, MD, Amarendra K. Neppalli, MD, Irl Brian Greenwell, MD, Kathy Edwards, PharmD, BCPS, BCOP, HRM, Laura Milligan, MSN, FNP, BC, AOCN, Lauren Pearce, FNP-BC, Brian T. Hess, MD

Blood (2019) 134 (Supplement_1): 5723.

https://doi.org/10.1182/blood-2019-128172

Published: 2019

Journal Articles

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Blood (2019) 133 (7): 676–687.

https://doi.org/10.1182/blood-2018-08-869008

Published: 2019

Includes: Supplemental data

Journal Articles

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blood (2017) 130 (6): 722–731.

https://doi.org/10.1182/blood-2017-04-779405

Published: 2017

Includes: Supplemental data

Journal Articles

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

Blood (2016) 128 (22): 1070.

https://doi.org/10.1182/blood.V128.22.1070.1070

Published: 2016

Journal Articles

Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)

Eunice S. Wang, MD, Richard M. Stone, MD, Martin S. Tallman, MD, Roland B. Walter, MD PhD, John R. Eckardt, MD, Robert Collins

Blood (2016) 128 (22): 1071.

https://doi.org/10.1182/blood.V128.22.1071.1071

Published: 2016

Journal Articles

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Eytan M. Stein, MD, Amir T. Fathi, MD, Courtney D DiNardo, MD, Daniel A Pollyea, MD, Ronan T Swords, MD PhD FRCPI, FRCPath, Gail J. Roboz, MD, Robert Collins, Mikkael A. Sekeres, MD, Richard M. Stone, MD, Eyal C Attar, Alessandra Tosolini, BS, Qiang Xu, PhD, Michael Amatangelo, PhD, Ira Gupta, MD, Robert D. Knight, MD, Stéphane De Botton, MD PhD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 343.

https://doi.org/10.1182/blood.V128.22.343.343

Published: 2016

Journal Articles

Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML

Swaminathan P. Iyer, MD, Yogesh Jethava, MD, Chatchada Karanes, MD, John R. Eckardt, MD, Robert Collins

Blood (2016) 128 (22): 3983.

https://doi.org/10.1182/blood.V128.22.3983.3983

Published: 2016

Journal Articles

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Blood (2015) 126 (23): 811.

https://doi.org/10.1182/blood.V126.23.811.811

Published: 2015

Journal Articles

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

Robert Collins, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jenny Chen, MDPhD, Meghan Macaraeg, BS, Vinoo Urity, MS, Blake Pond, MS, Abhijit Ramachandran, MS, Jorge E. Cortes, MD

Blood (2015) 126 (23): 4359.

https://doi.org/10.1182/blood.V126.23.4359.4359

Published: 2015

Journal Articles

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Courtney DiNardo, MD, Stéphane de Botton, Daniel A Pollyea, Eytan M Stein, Amir T. Fathi, MD, Gail J Roboz, MD, Robert Collins, MD, Ronan T. Swords, MDPhDFRCPI FRCPath, Ian W. Flinn, MD PhD, Jessica K Altman, Martin S Tallman, MD, Hagop M. Kantarjian, MD, Adnan Derti, Meredith Goldwasser, Malia Prahl, Bin Wu, Katharine Yen, Sam Agresta, Richard M. Stone, MD

Blood (2015) 126 (23): 1306.

https://doi.org/10.1182/blood.V126.23.1306.1306

Published: 2015

Journal Articles

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Haijiao Zhang, MD, Kevin Matthew Watanabe-Smith, BS, Daniel Bottomly, MS, Beth Wilmot, PhD, Shannon K. McWeeney, PhD, Hagop M. Kantarjian, MD, Judy Ho, Jeremy Davis, Blake Pond, MS, Gautam Borthakur, MD, Abhijit Ramachandran, MS, Jorge E. Cortes, Robert Collins, MD, Jeffrey W. Tyner, PhD

Blood (2015) 126 (23): 2468.

https://doi.org/10.1182/blood.V126.23.2468.2468

Published: 2015

Journal Articles

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

John Carl Panetta, Sharyn D Baker, PharmD, PhD, Hagop M. Kantarjian, MD, Clinton Stewart, Pharm.D., Blake Pond, MS, Meghan Macaraeg, BS, Tolu Makinde, PhD, Sheetal Vali, PhD, Naval Daver, MD, Abhijit Ramachandran, MS, Robert Collins, MD, Jorge E. Cortes, MD

Blood (2015) 126 (23): 3695.

https://doi.org/10.1182/blood.V126.23.3695.3695

Published: 2015

Journal Articles

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Blood (2015) 126 (23): 323.

https://doi.org/10.1182/blood.V126.23.323.323

Published: 2015

Journal Articles

Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)

Blood (2014) 124 (21): 3259.

https://doi.org/10.1182/blood.V124.21.3259.3259

Published: 2014

Journal Articles

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

Blood (2014) 124 (21): 163.

https://doi.org/10.1182/blood.V124.21.163.163

Published: 2014

Journal Articles

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Blood (2014) 124 (21): 115.

https://doi.org/10.1182/blood.V124.21.115.115

Published: 2014

Journal Articles

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors

Tony A. Navas, Mani Mohindru, Myka Estes, Jing Ying Ma, Lubomir Sokol, Perry Pahanish, Simrit Parmar, Edwin Haghnazari, Li Zhou, Robert Collins, Irene Kerr, Aaron N. Nguyen, Yin Xu, Leonidas C. Platanias, Alan A. List, Linda S. Higgins, Amit Verma

Blood (2006) 108 (13): 4170–4177.

https://doi.org/10.1182/blood-2006-05-023093

Published: 2006

Journal Articles

SD-208, a Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor, Can Stimulate Hematopoiesis in Myelodysplastic Syndrome Progenitors.

Amit Verma, Tony A. Navas, Jing Ying, Ma, Aaron N. Nguyen, Perry Pahanish, Mahesh Seetharam, Irene Kerr, Robert Collins, Mimi Kim, Mani Mohindru, Linda S. Higgins

Blood (2005) 106 (11): 3448.

https://doi.org/10.1182/blood.V106.11.3448.3448

Published: 2005

Journal Articles

Myelosuppresive Effects of Interferon [slpha] and Transforming Growth Factor β Can Be Reversed by Novel p38 MAPK Inhibitor SD-282 through Inhibition of Cell Cycle Arrest.

Mani Mohindru, Perry Pahanish, Robert Collins, Tony Navas, Linda Higgins, Amit Verma

Blood (2004) 104 (11): 4229.

https://doi.org/10.1182/blood.V104.11.4229.4229

Published: 2004

Journal Articles

Novel P38 MAP Kinase Inhibitor and Anti-P38 RNA Interference as Potential Therapeutic Approaches in Myelodysplastic Syndromes.

Mani Mohindru, Perry Pahanish, Efstratios Katsoulidis, Robert Collins, Thomas Rogers, Tony Navas, Linda Higgins, Leonidas Platanias, Amit Verma

Blood (2004) 104 (11): 470.

https://doi.org/10.1182/blood.V104.11.470.470

Published: 2004

NARROW

Outcomes of AML Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation with Adverse Risk Disease By European Leukemianet Classification: A Single Center Retrospective Analysis

Molecular remission and response patterns in patients with mutant- IDH2 acute myeloid leukemia treated with enasidenib

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 ( IDH2 ) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) with Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results from the Pyramid Trial (NCT00931918)

Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Exome Sequencing Informs Mechanisms of Clinical Resistance to the FLT3-D835 Inhibitor Crenolanib

Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib after Failure of Hypomethylating Agents (HMAs)

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR-MDS) after Failure of Hypomethylating Agents (HMAs)

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors

SD-208, a Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor, Can Stimulate Hematopoiesis in Myelodysplastic Syndrome Progenitors.

Myelosuppresive Effects of Interferon [slpha] and Transforming Growth Factor β Can Be Reversed by Novel p38 MAPK Inhibitor SD-282 through Inhibition of Cell Cycle Arrest.

Novel P38 MAP Kinase Inhibitor and Anti-P38 RNA Interference as Potential Therapeutic Approaches in Myelodysplastic Syndromes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only